Investors
Our investor proposition
GSK is a science-led global healthcare company that aims to deliver growth and improving returns to shareholders through the development of innovative pharmaceutical, vaccine and consumer healthcare products.
Key information
GSK reaches agreement to acquire TESARO
On 3 December 2018 we announced our agreement to acquire TESARO, an oncology-focused company based in the US for approximately $5.1bn.
Latest information
Latest press releases
- GSK reaches agreement to acquire TESARO, an oncology focused biopharmaceutical company
- GSK to divest Horlicks and other Consumer Healthcare nutrition products to Unilever
- Juluca (dolutegravir/rilpivirine), the first single pill, 2-drug regimen, for the maintenance treatment of HIV, granted marketing approval by Japan Ministry of Health, Labour and Welfare
2018 Third quarter results announcement
We announced our third quarter results for the period ended 30 September 2018 on Wednesday 31 October.